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Hypothesis: Malignant mesotheliomas (MMs) express vascular en-
dothelial growth factor receptor (VEGFR), platelet-derived growth
factor receptor, and cKIT. Sorafenib is a potent inhibitor of the
ras/raf/MEK pathway and also targets VEGFR and cKIT. We
evaluated the activity of sorafenib in patients with unresectable
mesothelioma.
Methods:MM patients who had received 0 to 1 prior chemotherapy
regimens were treated with sorafenib 400 mg orally twice daily
continuously. The primary end point was objective response.
ERK1/2 phosphorylation in archival tissues was correlated with
response and survival.
Results: A total of 51 patients were enrolled, 50 were evaluable and
included in the analysis. Three patients had a partial response (6%
[95% confidence interval  1.3–16.6%]), and 27 (54% [95% con-
fidence interval  39.3–68.2%]) had stable disease. Median pro-
gression-free survival and median overall survival (OS) were 3.6
and 9.7 months, respectively. Median survival was superior in
epithelioid histology versus other types (10.7 versus 3.7 months, p
0.0179). The difference in median OS between pretreated and
chemonaive patients was not statistically significant (13.2 versus 5
months, p  0.3117). Low/negative baseline tumor phospho-
ERK1/2 levels were associated with improved OS (13.9 versus 5.2
months, p  0.0066).
Conclusion: Sorafenib has limited activity in advanced MM pa-
tients, similar to that seen with other VEGFR tyrosine kinase
inhibitors. Additional studies of sorafenib in MM are not warranted.
Key Words:Mesothelioma, Sorafenib, Vascular endothelial growth
factor, Tyrosine kinase inhibitor, Clinical trial.
(J Thorac Oncol. 2010;5: 1655–1661)
The median survival of patients with unresectable malig-nant mesothelioma (MM) is a year or less.1 The only Food
and Drug Administration-approved treatment in this disease
is the combination of cisplatin with pemetrexed, which
achieves a response rate (RR) of 41%, time to progression of
6 months, and median overall survival (OS) of 12 months.1
There are no approved agents for patients who progress after
first-line chemotherapy.
Vascular endothelial growth factor (VEGF) is a mito-
gen for vascular endothelial cells. Acting through its recep-
tors vascular endothelial growth factor receptor (VEGFR)-1
(Flt-1) and VEGFR-2 (KDR), VEGF is necessary for main-
tenance of tumor vasculature.2 Treatment of mesothelioma
cell lines with recombinant human VEGF results in phos-
phorylation of VEGFR-1 and KDR and induces proliferation
of mesothelial cells,3 whereas the addition of VEGF neutral-
izing antibodies inhibits this proliferative effect. Serum
VEGF levels and tumor microvessel density correlate in
patients with mesothelioma inversely with survival.3,4 VEGF
also acts through raf/MEK/ERK kinase pathways.5 Multiple
growth factor receptors that act through the ras/raf/MEK/
ERK pathway such as EGFR, IGF-1R, PDGF-BB and the
receptor PDGFR-, and VEGFR1/2 are overexpressed or
aberrant in mesothelioma.3,6–8
Sorafenib (BAY 43-9006) is a potent inhibitor of the
raf/MEK/ERK signaling pathway with additional activity
against VEGFR-2, PDGFR-, and cKIT.9 It is an approved
agent in the treatment of renal cell carcinoma10 and hepato-
cellular carcinoma.11 Given the selective inhibitory activity of
sorafenib against raf, VEGFR-2, and PDGFR-, which are
potential therapeutic targets in mesothelioma, a phase II study
of sorafenib in unresectable mesothelioma was undertaken by
the Cancer and Leukemia Group B (CALGB).
PATIENTS AND METHODS
Eligibility Criteria
Eligible patients had histologically confirmed MM not
amenable to curative surgery, including sarcomatoid; epithe-
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loid; and mixed histologies of the pleura, peritoneum, peri-
cardium, and tunica vaginalis. Patients may have received no
more than one pemetrexed-containing chemotherapy regi-
men. No prior tyrosine kinase/signal transduction/angiogen-
esis inhibitor therapy was allowed. Any prior chemotherapy
or radiation must have been administered 4 weeks earlier.
Other eligibility criteria included Eastern Cooperative Oncol-
ogy Group performance status 0 or 1, measurable disease, no
therapeutic anticoagulation, no currently active second ma-
lignancy (completed treatment with 30% risk of relapse)
other than nonmelanoma skin cancers and carcinoma in situ
of the cervix, and laboratory values reflective of adequate
organ function (granulocytes 1500/mm3, platelets 100,000/
mm3, total bilirubin 1.5  upper limit of normal [ULN],
aspartate transaminase 2.5  ULN, creatinine 1.5 
ULN, International Normalized Ratio 1.5). Availability of
pathology blocks or slides from a core surgical biopsy was
required for evaluation of biologic correlates. The study was
approved by the Institutional Review Board at each center,
and all patients were required to sign the written informed
consent.
Study Treatment and Evaluation
Sorafenib was administered orally at a fixed dose of
400 mg twice daily. Twenty-eight days of treatment consti-
tuted one cycle. Treatment was continued until disease pro-
gression or unacceptable toxicity. Dose modifications in-
cluded dose level-1 (200 mg twice daily) and -2 (200 mg once
daily). Dose modification was recommended for grade 3
toxicities that were attributable to sorafenib. No dose re-
escalation was allowed. Evaluations included weekly blood
pressure measurements during the first treatment cycle and
computed tomography scans after every two cycles of treat-
ment. Disease burden was measured by RECIST criteria, and
in patients with solely a pleural rind, the modified RECIST
criteria were used.12
Immunohistochemical analysis of tumor phospho-
ERK1/2 (p-ERK1/2) was performed on archival tissue with
primary antibody p-ERK1/2 (Thr202/Tyr204; Cell Signaling
Technology, Beverly, MA). Staining of p-ERK1/2 was based
on intensity and degree of tumor staining. The results were
subsequently divided into two categories: high/medium
(group 1) and low/negative (group 2). BRAF mutation status
was determined by amplification of exons 11 and 15 with
flanking intronic primers followed by direct sequencing.
Specific primer sequences are available on request.
Statistical Methods
The primary end point of the study was objective RR.
Secondary endpoints included (1) OS and progression-free
survival (PFS), (2) toxicities, and (3) correlation of BRAF
mutations and p-ERK1/2 expression with antitumor activity.
A one-stage phase II design was used. A 44 patient sample
size was designed to differentiate RRs of 5 and 20% with
95% power by a two-sided test at 0.10 level of significance.
It was assumed that two-thirds (n 29) of the patients would
be treated on the study as second-line therapy and would
provide sufficient power for a subgroup analysis of outcome
by line of treatment. Specifically, 29 patients would provide
an 86% power to differentiate between 5 and 20% RR by a
two-sided test at 0.10 level of significance. RR (complete/
partial response) was calculated as well as its 95% confidence
interval (CI). OS and PFS curve were estimated by Kaplan-
Meier product limit method. The difference in OS and PFS
between pretreated versus chemonaive patients was com-
pared by log-rank test, so as that between histologic type
(epithelioid versus others). A step-wise multivariate Cox
regression with stay level of 0.15 and entry level of 0.20 was
also performed adjusting for baseline covariates such as
histologic type (epithelioid versus others), gender (female
versus male), performance status, and age. For exploratory
analysis of biologic markers, Fisher’s exact test tests were
performed to evaluate association between p-ERK1/2 expres-
sion and response. Cox models were fit to test the correlations
between PFS/OS and biomarker p-ERK1/2 while adjusting
for other baseline covariates such as histologic type (epithe-
lioid versus others), gender (female versus male), and age
(continuous variable). A step-wise method was used with the
same entry and stay criteria. Patient registration and data
collection were managed by the CALGB Statistical Center.
Data quality was ensured by careful review of data by
CALGB Statistical Center staff and by the study chairperson.
Statistical analyses were performed by CALGB statisticians.
RESULTS
Patient Characteristics
Fifty-one patients were enrolled between October 2004
and August 2005. One patient did not receive any treatment
because of hospitalization for pain. All other patients are
eligible and included in the analysis. Baseline characteristics
of the patients are described in Table 1. As expected for this
disease, most patients were men. The most frequent histology
was epithelioid, and the pleura was the predominant site of
involvement. Sixty percent (60%) of the patients had been
previously treated with pemetrexed-based chemotherapy.
A total of 252 cycles of sorafenib were administered to
the 50 patients. The median number of treatment cycles
administered was 3 (range, 1–32). Patients who received prior
chemotherapy underwent a median of 3.5 cycles (range,
1–32) of chemotherapy, whereas chemonaive patients re-
ceived a median of two cycles (range, 1–31) of chemotherapy
(p  0.66).
Toxicity
Grade 3 and 4 toxicities are displayed in Table 2. The
most common grade 3 toxicity was fatigue followed by
hand-foot syndrome. Grade 3 hypertension was uncommon
occurring only in 5% of patients, and there were no inci-
dences of grade 4 hypertension. The only grade 4 event was
fatigue in one patient. There were no grade 5 toxicities. Five
patients (10%) discontinued treatment because of toxicities.
Sixteen patients (32%) had dose reduction due to toxicity.
Skin toxicity in 10 patients and fatigue in 8 patients were the
most common reasons for dose reductions.
Efficacy Outcomes
Response data are available for 50 patients. Three
patients (6%, 95% CI  1.3–16.6%) had partial responses
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that lasted 3, 6, and 6 months. Stable disease occurred in
27 (54%, 95% CI  39.3–68.2%) of patients. We failed to
reject the null hypothesis that the RR is 5% or less. The
responses are illustrated as a waterfall plot in Figure 1,
which shows that tumor shrinkage and growth was about
equally distributed. The median duration of stable disease
was 7.95 months (95% CI  3.58–18.63). For patients
with prior chemotherapy, the RR is 3.33% (95% CI 
0–9.76%). For patients who are chemonaive, the RR is
10% (95% CI  0–23%). At the time of this analysis, three
of the treated patients are still alive for whom the fol-
low-up times are 32, 37, and 40 months. Two of the three
patients who demonstrated a response had not received
prior chemotherapy.
The median PFS and OS are 3.6 and 9.7 months,
respectively (Table 3; Figure 2). Patients who had received
previous chemotherapy survived for a median of 13.2
months, compared with 5.0 months for chemonaive pa-
tients; this difference was not statistically significant (p 
0.3117). One-year survival was also greater in the previ-
ously treated patients compared with those who were
chemonaive (57 versus 30%). As expected, median sur-
vival in patients with epithelioid histology was signifi-
cantly longer than in those with sarcomatoid or mixed
histology (10.7 versus 3.7 months, p  0.0179) (Table 3,
Figure 3).
Biologic Outcomes
Archival tissue for analysis was available on 42 pa-
tients. There were no BRAF mutations detected among these
samples. Of the 42 samples, 37 were evaluable for expression
of p-ERK1/2. ERK1/2 phosphorylation could not be evalu-
ated because of insufficient samples in the three patients who
developed a partial response. Thirty patients were p-ERK1/2
positive and seven patients were p-ERK1/2 negative. Re-
sponse to treatment (progressive disease, stable disease, in-
adequately assessed) neither correlated with presence or ab-
sence of p-ERK1/2 (p  0.6745) nor with level of expression
of p-ERK1/2 (low versus high) (p  0.1071). Similarly,
p-ERK1/2 expression (positive versus negative) had no
TABLE 1. Patient Demographic and Clinical Characteristics
(n  50)
Characteristics n (%)
Gender
Male 35 (70)
Female 15 (30)
Agea (yr)
50 3 (6)
50–59 8 (16)
60–69 17 (34)
70 22 (44)
Histology
Epithelioid 37 (74)
Sarcomatoid 4 (8)
Mixed subtype 7 (14)
Unknown 2 (4)
Site of origin
Pleura 45 (90)
Peritoneum 5 (10)
Previous chemotherapy
Yes 30 (60)
No 20 (40)
Performance status
0 11 (22)
1 39 (78)
a Median age: 69 years (range, 36–88 years).
TABLE 2. NCI CTC Grade 3 and 4 Toxicities after Sorafenib
Treatment
Toxicity
n  50
Grade 3 Grade 4
Hematological
Lymphopenia 2 (4) 0
Hemoglobin 1 (2) 0
Hemolysis 1 (2) 0
Nonhematological
Fatigue 12 (24) 1 (2)
Rash: hand-foot skin reaction 6 (12) 0
Dyspnea (shortness of breath) 4 (8) 0
Pain 3 (6) 0
Anorexia 2 (4) 0
Neuropathy: sensory 2 (4) 0
Hypertension 2 (4) 0
Hypotension 1 (2) 0
Values are given as n (%).
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FIGURE 1. Waterfall plot of tumor response. Three patients
(3%; labeled in green) achieved a partial response with sor-
afenib treatment.
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bearing on either PFS (hazard ratio [HR]  1.51, 95% CI 
0.65–3.50, p  0.342) or OS (HR  1.34, 95% CI 
0.55–3.23, p  0.5211). However, patients with medium or
high levels (group 1) had poorer OS than those with low or
negative (group 2) expression (HR  3.41, 95% CI 
1.41–8.25, p  0.0066) (Table 4, Figure 4). Because of the
small sample size, other factors such as previous treatments
and performance status were unable to be incorporated into
the Cox models.
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FIGURE 2. Kaplan-Meier survival curves for progression-free
survival (PFS) and overall survival. A, Median PFS was 3.6
months with 18% 1-year PFS. B, Median overall survival was
9.7 months with 46% 1-year survival.
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FIGURE 3. Kaplan-Meier survival curves for overall survival
by histology. Median overall survival was higher with epithe-
lioid histology than others (10.7 versus 3.7 months, p 
0.0179).
TABLE 3. Progression-Free and Overall Survivals Based on Prior Chemotherapy Treatment and
Histology
Overall Survival Progression-Free Survival
Median
(95% CI) (mo)
1-yr Survival
(95% CI) p
Median
(95% CI) (mo)
3-mo Survival
(95% CI) p
Overall population
n  50 9.7 (4.4–14.3) 46% (31.9–59) 3.6 (2.3–5.5) 58.0% (43.2–70.2)
Prior chemotherapy 0.3117 0.3181
Chemonaive, n  20 5.0 (3.0–12.2) 30% (12.3–50) 2.9 (1.9–5.5) 50.0% (27.1–69.2)
Prior chemotherapy,
n  30
13.2 (5.2–19.4) 56.7% (37.3–72.1) 3.7 (2.3–8.9) 63.3% (43.6–77.8)
Histology 0.0179 0.1034
Epithelioid, n  37 10.7 (5.2–24.1) 48.6% (32.0–63.4) 4.1 (2.1–8.0) 59.5% (42.0–73.2)
Other, n  13 3.7 (3.0–13.1) 38.5% (14.1–62.8) 3.4 (1.9–3.7) 53.9% (24.8–76.0)
CI, confidence interval.
TABLE 4. Progression-Free and Overall Survivals Based on
p-ERK1/2 Expression
n
Median
(mo) HR (95% CI) p
Progression-free survival 2.15 (0.94–4.90) 0.0701
pERK (negative/low) 22 6.7
pERK (medium/high) 15 2.1
Overall survival 3.41 (1.41–8.25) 0.0066
pERK (negative/low) 22 13.9
pERK (medium/high) 15 5.2
CI, confidence interval.
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DISCUSSION
MM continues to be a therapeutically challenging dis-
ease. Outcomes with cytotoxic agents have produced median
survivals of about a year or less.1,13–16 Given these findings,
there has been an interest to evaluate novel therapeutic agents
in patients with MM. Angiogenesis is a key event in carci-
nogenesis, and angiogenesis inhibitors have previously been
evaluated in mesothelioma. Targeting angiogenesis with a
multitude of agents with varied mechanism of action has
resulted in RRs of 0 to 23% and OS of 5.9 to 12.4 months
(Table 5). Our current study with single-agent sorafenib
produced a median survival of 9.7 months and is similar to
prior agents targeting this pathway. However, the study failed
to meet its primary end point. Furthermore, although out-
comes seemed to be better in previously treated patients, this
likely reflects patient selection as opposed to true clinical
activity of sorafenib in this patient population.
The outcome of mesothelioma patients treated with sor-
afenib was similar to other multitargeted kinase inhibitors (Table
5). As expected, patients with epithelioid histology fared better
than the rest. In a phase II study of sorafenib in hepatocellular
carcinoma, high p-ERK1/2 was associated with improved time
to progression than patients with low expression (p 
0.00034).17 These results were mirrored in our study with the
finding of improved OS in patients with low levels of baseline
p-ERK1/2. This improvement was seen as more than a doubling
in OS in comparison with those with medium or high levels of
expression. Low levels of p-ERK1/2 may be a reflection of the
proliferative state of the cancer. Hence, cancers with low levels
of p-ERK1/2 may in general be less aggressive and thus be
associated with a better outcome. Although sorafenib inhibits raf
signaling, this study did not specifically evaluate the effects on
p-ERK1/2 after sorfenib treatment. Furthermore, because sor-
afenib inhibits angiogenesis, biomarkers such as soluble
VEGFR or CD31 expression may help define patients likely to
benefit from treatment. Additional studies are needed to help
further clarify the role of these biomarkers, if any, with sorafenib
efficacy.
Although several studies with targeted agents in me-
sothelioma have been to date negative, many important les-
sons have been learned. First is the issue of patient selection.
In most malignancies, RR and survival decrease with advanc-
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FIGURE 4. Kaplan Meier survival
curves for overall survival time by
p-ERK expression. High baseline
pERK1/2 expression is associated with
poorer overall survival. Median sur-
vival was 5.2 months for medium/
high expression group (blue; group
1) and 13.9 months for negative/low
expression group (black; group 2);
p  0.0066.
TABLE 5. Phase II Studies of Anti-Angiogenic Agents in Mesothelioma
Drug Line of Therapy
Response
(%) SD (%)
TTP/PFS
(mo)
Median OS
(mo)
Vatalanib24 First line 8 72 10
Thalidomide25 First and second line 0 28 7.5
SU541626 Second line 11 38 2 (TTP) 12.4
Thalidomide27 Second line 6 50 8 wk (TTP) 11
Sunitinib28 Second line 23 3.5 (TTP) 5.9
AZD217129 Second line 9 33 3 (PFS) 10
Sorafenib
(this study)
First and second line 6 54 3.6 (PFS) 9.7
SD, stable disease; TTP, time to progression; OS, overall survival; PFS, progression-free survival.
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ing lines therapy. However, such a consistent association in
mesothelioma trials is lacking, and median survival of 11 to
12 months in pretreated patients is seen. This raises the
possibility that patients ineligible for cytotoxic chemotherapy
because of performance status or other factors and hence with
poorer prognoses are enrolled on front-line noncytotoxic
chemotherapy trials, thus blunting the effects of targeted
therapy in the front-line setting. Another important consider-
ation in addition to performance status is the age of patients
on mesothelioma trials. Almost half the patients in this study
were 70 years or older, which is consistent with the median
age of diagnosis of mesothelioma (74 years).18 This feature
has to be accounted for in the design of future trials, and
mesothelioma trials will need to cater to the elderly.
The heterogeneity within mesothelioma may also con-
found the results of an investigational agent if evaluated in a
single-arm study. For example, in a randomized study of
cisplatin/gemcitabine with or without bevacizumab, although
survival on both arms exceeded the survival in other mesothe-
lioma studies, long-term follow-up failed to show a benefit
with the addition of bevacizumab to chemotherapy (median
survival is 14.7 months in chemotherapy arm and 15.6
months in bevacizumab arm, p  0.91).19 In the absence of
the chemotherapy control arm, this study would have led to
the spurious conclusion that bevacizumab improves survival
with chemotherapy. Hence, future studies must strongly con-
sider a randomized phase II design for drug selection. There
has been no clear association between RRs and survival; most
studies have shown low RRs and often targeted agents do not
typically result in radiologic responses. Recently, multivari-
ate Cox regression analyses of 523 patients treated on
EORTC (European Organization of Research and Treatment
of Cancer) mesothelioma trials led to the development of a
performance status, stage, and histology-based prognosis in-
dex nomogram.20 This nomogram separated patients into four
risk categories with graded PFS. Perhaps it is time for a
paradigm shift in mesothelioma trials to adopt survival end
points such as PFS or OS as opposed to responses rates.
In conclusion, this study is another example of an
angiogenesis inhibitor with limited activity in mesothelioma.
For this class of agents, future trials should include a chemo-
therapy backbone. Such chemotherapy should be tailored to
the elderly and decreased functional status, with end points
and study design that can adequately reflect the heterogeneity
of this disease. Needless to say, therapy for mesothelioma
will need to move toward targets beyond angiogenesis. Other
likely targets include the proteosome, histone deacetylase,
Src, mesothelin, insulin-like growth factor, and MEK, which
are currently being investigated in clinical trials.21–23
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